Project_MDS — Lab Mavilio

Characterization of innate lymphoid compartment in bone marrow niche of myelodysplastic syndrome patients

Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms with variable clinical outcomes and an increased risk of progression to acute myeloid leukemia (AML). The diagnosis of MDS is challenging and frontline pharmacological therapies (i.e. hypomethylating agents) are not curative.

Through a multi-omic approach, we aim at characterizing innate immunity, disclosing its impact in inducing a tolerant immune environment in MDS that, in turn, increases genomic instability and speeds progression to AML.

The final goal of this project is to understand the role of innate lymphocytes in MDS pathogenesis and prognosis, to improve the management of MDS in terms of diagnosis, risk stratification and response to therapy and to find out tumor immune escape mechanisms that could be targeted to ameliorate patient prognosis.

TEAM

Clara Di Vito PhD - Senior staff scientist

Alessandro Frigo - Post-doctoral fellow

Lara Orlandi - PhD student

Paolo Marzano - PhD student, bioinformatician

Annalisa Imperiali - PhD student, bioinformatician

FUNDing

Ministero della Salute
Bando Giovani ricercatori, Ricerca Finalizzata 2021

Project ID: GR-2021-12374166

Phenotypic and molecular characterization of innate lymphoid cells in Myelodisplastic syndromes: towards the comprehension of their role in disease etiology and prognosis

collaborations

Genomics of Hematological Malignances Lab
IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy

Humanitas Cancer Center
IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy

Department of Medical and Surgical Sciences
Bologna University, Italy

Department of Physics and Astronomy
DIFA, University of Bologna, Bologna, Italy

related publications

Persistence of KIRneg NK cells after haploidentical hematopoietic stem cell transplantation protects from human cytomegalovirus infection/reactivation
Di Vito C, Coianiz N, Calvi M, Terzoli S, Zaghi E, Puccio S, Frigo A, Mariotti J, De Philippis C, Mannina D, Sarina B, Mineri R, Le-Trilling VTK, Trilling M, Castagna L, Bramanti S, Santoro A and Mavilio D.
Front. Immunol. 2024 Jan;14:1266051. doi: 10.3389/fimmu.2023.1266051.
Development of Human ILCs and Impact of Unconventional Cytotoxic Subsets in the Pathophysiology of Inflammatory Diseases and Cancer
Calvi M, Di Vito C, Frigo A, Trabanelli S, Jandus C, Mavilio D.
Front Immunol. 2022 May 26;13:914266. doi: 10.3389/fimmu.2022.914266.
Single-cell profiling identifies impaired adaptive NK cells expanded after HCMV reactivation in haploidentical HSCT
Zaghi E, Calvi M, Puccio S, Spata G, Terzoli S, Peano C, Roberto A, De Paoli F, van Beek JJ, Mariotti J, De Philippis C, Sarina B, Mineri R, Bramanti S, Santoro A, Le-Trilling VTK, Trilling M, Marcenaro E, Castagna L, Di Vito C, Lugli E, Mavilio D.
JCI Insight. 2021 Jun 22;6(12):e146973. doi: 10.1172/jci.insight.146973.
Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies
Zaghi E, Calvi M, Di Vito C, Mavilio D.
Front Immunol. 2019 Nov 28;10:2794. doi: 10.3389/fimmu.2019.02794.
The early expansion of anergic NKG2Apos/CD56dim/CD16neg natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation
Roberto A, Di Vito C, Zaghi E, Mazza EMC, Capucetti A, Calvi M, Tentorio P, Zanon V, Sarina B, Mariotti J, Bramanti S, Tenedini E, Tagliafico E, Bicciato S, Santoro A, Roederer M, Marcenaro E, Castagna L, Lugli E, Mavilio D.
Haematologica. 2018 Aug;103(8):1390-1402. doi: 10.3324/haematol.2017.186619.